Dostarlimab 50 mg/ml sol. Inj. Frs. 10 ml IV
TED · 370892-2026Award noticeawardedNo deadline given
Buyer
NameInstituto Português de Oncologia do Porto Francisco Gentil, EPE
CountryPT
Published2026-06-01
Deadline—
Value
Estimated—
Awarded€100 · 100 EUR
WinnerGlaxoSmithkline - Produtos Farmacêuticos, Lda.
Who already wins at this buyer
Firms with recorded awards from Instituto Português de Oncologia do Porto Francisco Gentil, EPE in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| Air Liquide Medicinal, S.A | 1 | €843,097 | 2026-05-27 |
| Novartis Farma - Produtos Farmacêuticos , S.A | 1 | €783,120 | 2026-05-08 |
| Smith & Nephew, Lda | Paul Hartmann, Lda. | 1 | €582,427 | 2026-05-11 |
| TERUMO BCT PORTUGAL, UNIPESSOAL LDA. | 1 | €558,440 | 2026-05-07 |
| Expomédica, Lda | 1 | €368,800 | 2026-05-08 |
CPV codes
33600000 Medical equipment & pharmaceuticalsDescription
Dostarlimab 50 mg/ml sol. Inj. Frs. 10 ml IV
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-06-24 | 2023/0491 - IPILIMUMAB [5 MG/ML 10 ML CONC P/ SOL P/ PERF FRS] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 91% |
| 2026-05-12 | 2023/0491 - DARATUMUMAB [120 MG/ ML 15 ML SOL INJ FRS] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 91% |
| 2026-06-02 | 2023/0491 - OCRELIZUMAB [300 MG/ 10 ML SOL INJ FRS] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 91% |
| 2026-06-09 | 2025/1746 - EMICIZUMAB [150 MG/ML 0,7 ML SOL INJ FRS] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 90% |
| 2026-06-09 | 2023/0491 -PERTUZUMAB + TRASTUZUMAB [60 + 60 MG/ML SOL INJ FRS] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 90% |
| 2026-06-09 | 2025/1746 -EMICIZUMAB [150 MG/ML 0,4 ML SOL INJ FRS] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 90% |